Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

Background: Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival prolongation, the efficacy remains unsatisfactory,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Sirui, Yu, Jing, Huang, Qiyue, Zhou, Nan, Xiong, Xianze, Gou, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742598/
https://www.ncbi.nlm.nih.gov/pubmed/36518664
http://dx.doi.org/10.3389/fphar.2022.1037646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742598/
https://www.ncbi.nlm.nih.gov/pubmed/36518664
http://dx.doi.org/10.3389/fphar.2022.1037646

Ejemplares similares